Why the study?
Stark differences exist between wealthy and developing nations in CIED use, while rhythm-related diseases impose a significant burden in low- and middle-income countries.
Proposes a framework and outlines regulatory pathways for the reuse of cardiac implantable electronic devices to improve global equity in cardiac care.
Offers a regulatory roadmap for CIED reuse; leaves open prospective safety and equity trials before adoption.
A nation's health and economic development are inextricably and synergistically connected. Stark differences exist between wealthy and developing nations in the use of cardiac implantable electronic devices (CIEDs). Cardiovascular disease is now the leading cause of death in low- and middle-income countries (LMIC), with a significant burden from rhythm-related diseases. As science, technology, education, and regulatory frameworks have improved, CIED recycling for exportation and reuse in LMIC has become possible and primed for widespread adoption. In our manuscript, we outline the science and regulatory pathways regarding CIED reuse. We propose a pathway to advance this technology that includes creating a task force to establish standards for CIED reuse, leveraging professional organizations in areas of need to foster the professional skills for CIED reuse, collaborating with regulatory agencies to create more efficient regulatory expectations and bring the concept to scale, and establishing a global CIED reuse registry for quality assurance and future science.
No takes yet. Share an insight, caveat, or question.
Alyesh et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: